Gujarat Themis Biosyn shares fall 3.8% on clarified Rs 404 preferential issue terms

According to the corrigendum dated 21 September 2026 (pages 1–4), Gujarat Themis Biosyn has reworked the floor price calculation and aligned its preferential issue proposal with SEBI ICDR norms, but kept the overall fundraising plan intact.

Key updated terms from the filing:

• The company now proposes to issue "up to 82,92,081 equity shares" of face value Rs 1 each (page 2).
• The shares will be issued "at a price of Rs. 404 per equity share (the Issue Price), aggregating up to Rs. 335,00,00,724/-" (page 2).
• The corrigendum states that "Wherever the number of total Equity Shares and amounts appears in the Resolution, explanatory statement and disclosures, shall be read as 82,92,081 and Rs. 335,00,00,724 respectively and issue price as Rs. 404 per share" (page 4).

In other words, the quantum of capital to be raised — Rs 335,00,00,724 — is unchanged, but the exact number of shares and the pricing mechanics have been corrected to match the SEBI ICDR formula.

The live market commentary around the stock points to the preferential issue pricing as the main trigger for the 3.8% slide. The issue price of Rs 404 per share, as disclosed in the corrigendum, is close to but below where the stock had been trading recently, and investors appear to be treating it as a discounted equity raise that dilutes existing holdings.

The filing lays out the pricing logic in detail (page 3):

• "The floor price for the Equity Shares is Rs. 403.82, as per the pricing formula prescribed under the SEBI ICDR Regulations for the Preferential Issue and is the highest of the following."
• 90 trading days VWAP preceding the relevant date: "Rs. 384.09 per equity share."
• 10 trading days VWAP preceding the relevant date: "Rs. 403.82 per equity share."
• The company then states: "It has approved the issue price of Rs. 404/- per Equity Share (including premium of Rs. 403 per share), being not less than the floor price computed in accordance with Chapter V / applicable provisions of the SEBI ICDR Regulations."

By explicitly anchoring the issue at Rs 404 — just above the calculated floor of Rs 403.82 — the board has chosen a price that is compliant but still meaningfully below where the stock had been changing hands before the announcement, according to the market read. That gap is what traders are reacting to: the lower the issue price versus the prevailing market price, the more value is effectively transferred to new investors at the expense of existing shareholders.

The corrigendum also refreshes the shareholding math, which helps quantify the dilution (page 4):

• Total equity shares outstanding will rise from "13,01,51,705" pre-issue to "13,84,43,786" post-issue.
• Promoters and promoter group holding goes from "7,72,18,083" shares ("59.33"%) to "8,34,06,204" shares ("60.25"%).
• Public shareholding falls from "40.67"% to "39.75"%.

Within that, the key promoter group subscriber is named explicitly (page 4):

• "Pharmaceutical Business Group (India) Limited, a promoter group entity is intended to subscribe to Equity Shares as mentioned in the resolution and the Statement."

The updated allottee table (page 2) shows how the Rs 335,00,00,724 is split at the Rs 404 issue price:

1. Pharmaceutical Business Group (India) Limited – "61,88,121" shares for "250,00,00,884" (promoter group).
2. Yusuf Khwaja Hamied – "2,47,526" shares for "10,00,00,504" (public).
3. Special Situation India Fund – "4,64,108" shares for "18,74,99,632" (public).
4. India Special Assets Fund III – "6,90,594" shares for "27,89,99,976" (public).
5. ISAF III Onshore Fund – "7,01,732" shares for "28,34,99,728" (public).

A separate table (page 4) details the pre- and post-allotment holdings of these investors. For example, Pharmaceutical Business Group (India) Limited will move from "5,07,16,440" shares ("38.97"%) to "5,69,04,561" shares ("41.08"%).

For existing minority shareholders, this confirms two things:

• The absolute dilution in percentage terms, as total shares rise to 13,84,43,786.
• That the promoter group is using the preferential route to lift its stake above 41%, while select institutional investors and a named public investor come in at the same Rs 404 price.

Even though promoter participation can be seen as a vote of confidence, the combination of fresh equity issuance and a price set near the regulatory floor tends to weigh on the stock in the short term.

The corrigendum also tightens the description of how the Rs 335,00,00,724 will be deployed (page 3):

• "Redemption of Non-convertible debenture (NCDs) and/or Repayment / prepayment of the borrowing and interest thereon" tied to acquiring "100% equity stake in MicroBiopharm Japan Co., Ltd." – "310,00,00,724" with a "12 months" timeline.
• "General Corporate Purposes (not exceed 25%)" – "25,00,00,000" with a "12 months" timeline.

The company also clarifies interim deployment (page 3):

• Pending full use, proceeds may be invested "in deposits in scheduled commercial banks, securities issued by government of India and/or creditworthy instruments as permitted under applicable laws / guidelines."

Investors already knew from earlier disclosures that the Japan acquisition was being funded partly via high-coupon NCDs; this corrigendum effectively confirms that a large chunk of the preferential issue will go towards redeeming those NCDs or repaying related borrowings, and only Rs 25,00,00,000 is earmarked for general corporate purposes.

From a balance-sheet perspective, swapping expensive debt for equity can reduce interest burden over time. But in the near term, equity markets often mark down stocks when they see:

• A sizeable increase in share count (here, to 13,84,43,786 shares post-issue).
• A preferential issue priced close to the regulatory floor, at Rs 404, which can be read as management signalling limited room to price higher.

It is also notable what the filing does not contain. The corrigendum is purely about aligning the AGM resolution with "applicable laws / SEBI ICDR Regulations" (page 2). It does not:

• Provide any new revenue, profit or margin numbers.
• Update guidance or comment on the performance of MicroBiopharm Japan Co., Ltd.

The filing explicitly states that "There is no material changes. The change mainly in number of shares is due to rectifying error in floor price calculation and the same is considered in the interest of the Company" (page 4).

That leaves the market to trade largely on structure and pricing: a Rs 404 per share preferential issue, Rs 335,00,00,724 in fresh equity, and a modest increase in promoter holding. With no offsetting positive surprise on earnings or outlook in this document, the clarified dilution mechanics appear to be the dominant driver of Gujarat Themis Biosyn’s 3.8% intraday decline to Rs 411.

This article is for information purposes only and is not investment advice.